Efficacy of infliximab for hidradenitis suppurativa: Assessment of clinical and biological inflammatory markers

Acta Dermato-Venereologica

Volumn 91, Issue 2, 2011, Pages 169-171

  Delage, Maïa ^a   Samimi, Mahtab ^a   Atlan, Michaël ^b   Machet, Laurent ^a,b   Lorette, Gérard ^a   Maruani, Annabel ^a,b  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CYPROTERONE ACETATE; GLUCONATE ZINC; INFLIXIMAB; ISOTRETINOIN;

ABSCESS; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; ECZEMA; FEMALE; HUMAN; INFLAMMATION; MALE; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; SUPPURATIVE HIDRADENITIS; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; DRUG ERUPTIONS; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; PAIN; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952421719     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-1025     Document Type: Article

References (26)

1. Matusiak Ł, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol 2010; 62: 706-708.
2. Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59: 596-601.
3. Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009; 61: 51-57.
4. Matusiak L, Bieniek A, Szepietowski JC. Hidradenitis suppurativa and associated factors: still unsolved problems. J Am Acad Dermatol 2009; 61: 362-365.
5. Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161: 831-839.
6. Sellheyer K, Krahl D. Hidradenitis suppurativa" is acne inversa! An appeal to (finally) abandon a misnomer. Int J Dermatol 2005; 44: 535-540.
7. Jemec GBE. Hidradenitis suppurativa. J Cutan Med Surg 2003; 7: 47-56.
8. Attanoos RL, Appleton MA, Douglas-Jones AG. The pathogenisis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands. Br J Dermatol 1995; 33: 254-258.
9. Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inverse. A clinicopathological study of earlier lesions. Br J Dermatol 1996; 135: 721-725.
10. Brown TJ, Rosen T, Orengo IF. Hidradenitis suppurativa. South Med J 1998; 91: 1107-1114.
11. Antonucci A, Negosanti M, Negosanti L, Iozzo I, Varotti C. Acne inversa treated with infliximab: different outcomes in 2 patients. Acta Derm Venereol 2008; 88: 274-275.
12. Moschella SL. Is there a role for infliximab in the current therapy of hidradenitis suppurativa? A report of three treated cases. Int J Dermatol 2007; 46: 1287-1291.
13. Pedraz J, Daudén E, Pérez-Gala S, Goiriz-Valdés R, Fernández-Peñas P, García-Diez A. Hidradenitis suppurativa. Response to treatment with infliximab. Actas Dermosifiliogr 2007; 98: 325-331.
14. Usmani N, Clayton TH, Everett S, Goodfield MD. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol 2007; 32: 204-205.
15. Thielen AM, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol 2006; 155: 1105-1107.
16. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat 2005; 16: 58-61.
17. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 2003; 139: 1540-1542.
18. Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2003; 49: S275-276.
19. Fardet L. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol 2007; 56: 624-628.
20. Sullivan TP, Welsh E, Kedel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br J Dermatol 2003; 149: 1046-1049.
21. Fernandez-Vozmediano JM, Armario-Hita JC. Infliximab for the treatment of hidradenitis suppurativa. Dermatology 2007; 215: 41-44.
22. Mekkes JR, Bos JD. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa. Br J Dermatol 2008; 158: 370-374.
23. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010; 62: 205-217.
24. Haslund P, Lee RA, Jemec GB. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors. Acta Derm Venereol 2009; 89: 595-600.
25. Lavogiez C, Delaporte E, Darras-Vercambre S, Martin De Lassalle E, Castillo C, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology 2010; 220: 147-153.
26. Matusiak L, Bieniek A, Szepietowski JC. Increased serum tumour necrosis factor alpha in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-alpha agents? Acta Derm Venereol 2009; 89: 601-603.